Sign inJoin waitlistJoin the waitlist

Ranee Mehra

Adjunct Professor · Univ of Maryland Sch of Med

Credentials: · · · · ·

History

Univ of Maryland Sch of Med
Present
Univ of Maryland Sch of Med · University of Maryland Capital Region Health
Present

Yale Medical School
2004–2006
Internal Medicine
NYU Langone Hospitals
1999–2002
New York University
1999–2002
New York University Grossman School of Medicine
1995–1999
Massachusetts Institute of Technology
1991–1995

Research

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase…
The Lancet Oncology · 2016 · 1,435 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet · 2019 · 1,414 citations
Ceritinib in ALK-rearranged non-small-cell lung cancer
New England Journal of Medicine · 2014 · 1,177 citations

Barbara Burtness
42 papers
JR
John Ridge
24 papers
Jason Molitoris
18 papers
Miriam Lango
17 papers
Thomas Galloway
15 papers
Kyle Hatten
12 papers
Rodney Taylor
12 papers
Jeffrey Wolf
11 papers
Katherine Scilla
11 papers
Christian Rolfo
10 papers
Hyunseok Kang
10 papers
Kevin Cullen
10 papers

Grants

Study of Biological and Radiographic Biomarkers and Association with Ancestry and Survival Disparities in Oral Cavity Squamous Cell Carcinoma Using AI Approaches
National Institute of Dental and Craniofacial Research · R01
PI · $2M · University of Maryland Baltimore
2024–2029
University of Maryland Greenebaum Cancer Centersupport Grant
National Cancer Institute · P30
Project lead · $308.2K · University of Maryland Baltimore
2008–2027

Clinical trials

Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab
Principal investigator · Completed
ECOG-ACRIN Cancer Research Group
2010
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Completed · Phase 1
Fox Chase Cancer Center
2009–2019
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
Principal investigator · Terminated · Phase 2
Fox Chase Cancer Center
2006–2009
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029